Drug Trial Radar · NCT03729245
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Last checked: Nov 19, 2026Latest source record: Apr 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
623
Actual
Start
Dec 18, 2018
Primary completion
Jan 7, 2022
Study completion Oct 19, 2022
Sponsor
- Lead sponsor
- Nektar TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Nov 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to compare the objective response rate (ORR) and overall survival (OS) of bempegaldesleukin (NKTR-214: BEMPEG) combined with nivolumab to that of tyrosine kinase inhibitor (TKI) monotherapy (sunitinib or cabozantinib) in IMDC intermediate- or poor-risk patients and IMDC all-risk patients with previously untreated advanced renal cell carcinoma (RCC).
Conditions
- Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
Interventions
bempegaldesleukinBiological
Specified dose on specified days
sunitinibDrug
Specified dose on specified days
nivolumabBiological
Specified dose on specified days
cabozantinibDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCCTime frame: Approximately 32 months
- Overall Survival (OS) in IMDC All-Risk and Intermediate- or Poor-risk Patients With Previously Untreated Advanced RCCTime frame: Approximately 32 months
Locations
96 sites in 10 countries. Site status is shown where the registry gives one.
Alaska Urological
Anchorage, Alaska
Western Regional Medical Center - CTCA - PPDS
Goodyear, Arizona
CARTI Cancer Center
Little Rock, Arkansas
City of Hope National Medical Center
Duarte, California
University of California Irvine
Orange, California
Innovative Clinical Research Institute
Whittier, California
University of Miami
Miami, Florida
Winship Cancer Institute, Emory University
Atlanta, Georgia
Tulane Medical Center
New Orleans, Louisiana
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
North Shore Hematology Oncology Association PC
Port Jefferson Station, New York
Kettering Medical Center
Kettering, Ohio
Providence Cancer Institute, Franz Clinic
Portland, Oregon
Lehigh Valley Physician Group (LVPG) - Hematology Oncology
Allentown, Pennsylvania
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
Eastern Regional Medical Center - CTCA
Philadelphia, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
Huntsman Cancer Hospital - PPDS
Salt Lake City, Utah
Centro de Investigación Pergamino S.A
Buenos Aires, Argentina
Centro Médico Austral
Buenos Aires, Argentina
Instituto Médico Especializado Alexander Fleming
Buenos Aires, Argentina
Centro Médico Privado CEMAIC
Córdoba, Argentina
Sanatorio Allende S.A.
Córdoba, Argentina
Sanatorio Privado Duarte Quirós, de Clínica Colombo S.A.
Córdoba, Argentina
Centro Oncologico Riojano Integral (cori)
La Rioja, Argentina
Hospital Provincial Del Centenario
Rosario, Argentina
CAIPO Centro para la atención integral del paciente oncológico
San Miguel de Tucumán, Argentina
Sanatorio Parque de Rosario
Santa Fe, Argentina
Centro de Investigación Clínica - Clínica Viedma
Viedma, Río Negro Province, Argentina
Orange Cancer Centre
Orange, New South Wales, Australia
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia
Macquarie University
Sydney, New South Wales, Australia
Adelaide Cancer Centre
Kurralta Park, South Australia, Australia
Barwon Health
Parkville, Victoria, Australia
Instituto de Pesquisas Clínicas Para Estudos Multicêntricos
Caxias do Sul, Brazil
Instituto Do Câncer Do Ceará ICC
Fortaleza, Brazil
Animi
Lages, Brazil
Instituto Nacional de Câncer
Rio de Janeiro, Brazil
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.